Dizal Pharma

Executive Summary

Dizal Pharma, a clinical-stage biopharmaceutical company based in Shanghai, focuses on developing novel small-molecule therapeutics for cancer and immune diseases. Its pipeline includes sunvozertinib (DZD9008), a best-in-class EGFR exon20 insertion mutation inhibitor for non-small cell lung cancer (NSCLC), and DZD8586, a BTK inhibitor for B-cell malignancies. The company has demonstrated promising clinical data, with sunvozertinib receiving breakthrough therapy designation in China and showing durable responses in platinum-pretreated patients. Dizal is also advancing preclinical candidates targeting novel pathways. With a differentiated approach addressing validated targets with improved selectivity, Dizal is positioned to capture significant market share in the competitive oncology space. The company went public on the Shanghai STAR Market in 2021, providing capital to support its pipeline advancement.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 data readout for sunvozertinib (DZD9008) in 1L EGFR exon20ins NSCLC80% success
• H1 2027NDA submission for sunvozertinib in 2L+ EGFR exon20ins NSCLC in China90% success
• Q2 2026Initial Phase 1/2 data for DZD8586 (BTK inhibitor) in B-cell malignancies60% success